TNM-001

Primary objective: To evaluate the safety and tolerability of a single intramuscular (IM) dose of TNM001 injection in healthy preterm and term infants Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of a single intramuscular dose of TNM001 injection in healthy preterm and term infants 2) To evaluate the PD characteristics of a single IM dose of TNM001 injection in healthy preterm and term infants 3) To evaluate the immunogenicity of a single IM dose of TNM001 injection in healthy preterm and term infants Exploratory objective: To explore the incidence of RSV-induced lower respiratory tract infections requiring medical intervention in healthy preterm and term infants after receiving TNM001 injection